Kairos Pharma, Ltd. (KAPA) is a publicly traded Healthcare sector company. As of September 9, 2026, KAPA trades at $1.82 with a market cap of $6.23M and a P/E ratio of -6.03. KAPA moved +2.88% today. Year to date, KAPA is -64.39%; over the trailing twelve months it is -86.33%. Its 52-week range spans $1.51 to $14.77. Analyst consensus is buy with an average price target of $12.00. Rallies surfaces KAPA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies tracks the latest KAPA news, catalysts, market updates, source links, and AI summaries when news is available.
| Metric | Value |
|---|---|
| Price | $1.82 |
| Market Cap | $6.23M |
| P/E Ratio | -6.03 |
| EPS | $-0.30 |
| Dividend Yield | 0.00% |
| 52-Week High | $14.77 |
| 52-Week Low | $1.51 |
| Volume | 3 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-5.45M |
| Gross Margin | 0.00% |
2 analysts cover KAPA: 0 strong buy, 2 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $12.00.